Pharmaceutical company Eli Lilly and Company has tested an experimental intravenous drug called donanemab, which is expected to slow cognitive decline in Alzheimer's patients.

According to CNN, 257 patients with early symptoms of Alzheimer's disease took part in the study - 131 people received donanemab and 126 received placebo.

A study found that donanemab slowed down cognitive decline in Alzheimer's patients by 32% at 76 weeks compared with those who received a placebo. The researchers also analyzed the effect of the drug on the accumulation of beta-amyloid plaques and tau proteins, which are considered hallmarks of Alzheimer's disease.

At week 52, almost 60% of the participants achieved negative amyloid status. At week 76, the level of amyloid plaques decreased 85 units more than the placebo group. When the readings dropped, donanemab was discontinued. Despite this, the development of the disease continued to be inhibited.